

Original Research Article

## Positive Correlation Found Between HDL and TSH in Hyperthyroidism

Kaushik Kar, Satwika Sinha

Assistant Professor, Department of Biochemistry, Calcutta National Medical College, Kolkata.

Corresponding Author: Kaushik Kar

Received: 18/09/2015

Revised: 18/10/2015

Accepted: 27/10/2015

### ABSTRACT

**Background:** Hyperthyroidism produces oxidative stress and dyslipidemia. We planned to measure serum ceruloplasmin and superoxide dismutase which are known antioxidants and lipid profile in hyperthyroid patients.

**Materials and methods:** 41 hyperthyroid patients and 32 control subjects were taken for the study. Study subjects were taken according to the inclusion and exclusion criteria after taking permission from the institutional ethics committee. Serum T4, TSH, ceruloplasmin, superoxide dismutase, and lipid profile were estimated. T4 and TSH were estimated by ELISA whereas ceruloplasmin, superoxide dismutase and lipid profile were estimated by autoanalyser.

**Results:** Significant decrease of serum TSH ( $P < 0.0001$ ), serum HDL ( $P < 0.0001$ ) whereas Significant increase of serum ceruloplasmin ( $p < 0.0001$ ), and superoxide dismutase ( $p < 0.0001$ ) were found in hyperthyroids when compared to controls. Furthermore we observed positive correlation between serum TSH and serum HDL ( $r = 0.9642$ ,  $p < 0.05$ ).

**Conclusion:** Hyperthyroidism demands antioxidants to prevent the deterioration of the condition. It also requires correction of HDL level to prevent cardiovascular complications.

**Key words:** HDL, TSH, Hyperthyroidism.

### INTRODUCTION

Commonest endocrine disorders of world are the thyroid diseases. Population study estimated about 108 million people in India are suffering from endocrine and metabolic diseases of which thyroid abnormalities contribute about 42 million.

<sup>(1)</sup> Hyperthyroidism may results from generalised thyroid gland overactivity or due to some other causes. <sup>(2)</sup> However clinical, physiological and biochemical alterations occur when tissues are exposed to increased concentrations of thyroid hormones. <sup>(3)</sup> Different studies also supported that functional abnormalities of hyperthyroidism virtually affects many organ systems. <sup>(4)</sup>

An epidemiological study in Cochin has shown that subclinical and overt hyperthyroidism was present in 1.6% and 1.3% of subjects in community. <sup>(5)</sup> In another hospital based study at Pondicherry, 0.6% and 1.2% of female subjects were observed as hyperthyroids. <sup>(6)</sup>

In hyperthyroidism, due to increased tissue oxygen utilization, erythrocytes take part in oxygen distribution is more exposed to this molecule. This may results in increased rates of hemoglobin oxidation and methemoglobin production that may in turn, leads to an increment in production of superoxide radicals and alterations in antioxidant defense status. <sup>(7)</sup> Acceleration

of the basal metabolic rate and the energy metabolism of tissues in several

Mammalian species represent one of the major functions of thyroid hormones. Accumulating evidence has suggested that the hypermetabolic state in hyperthyroidism is associated with increases in free radical production and lipid peroxide levels. Also, the response of the antioxidant system to hyperthyroidism is unclear. <sup>(8)</sup> Several studies <sup>(9-11)</sup> have been performed to assess the levels of antioxidant enzymes in specific organs of experimental animals with hyperthyroidism. The data regarding the blood levels of antioxidant enzymes in untreated hyperthyroidism is limited and contrasting in the literature. <sup>(12)</sup>

Under physiological conditions, ROS generation is controlled by a large number of anti-free radical systems which act as protective mechanisms. These systems consist of antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase, as well as non-enzymatic antioxidants, among which the most important are vitamins C and E, carotenoids, glutathione and uric acid. <sup>(13)</sup> The disturbance of the pro-oxidant / antioxidant balance resulting from the increased production of ROS inactivation of detoxification systems or excessive consumption of antioxidants is a causative factor in the oxidative damage of cellular structures and molecules, such as lipids, proteins and nucleic acids. <sup>(14,15)</sup>

Serum ceruloplasmin is an enzymatic protein belonging to the circulating system of antioxidative protection and also playing a role in the cell-mediated immunity. <sup>(16)</sup>

In metabolism of lipids, thyroid hormones induce the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is the first step in cholesterol biosynthesis. Moreover, triiodothyronine ( $T_3$ ) upregulates LDL receptors by controlling the LDL receptor

gene activation. This  $T_3$ -mediated gene activation is done by the direct binding of  $T_3$  to specific thyroid hormone responsive elements (TREs). <sup>(17)</sup> Furthermore,  $T_3$  controls the sterol regulatory element-binding protein-2 (SREBP-2), which in turn regulates LDL receptor's gene expression. <sup>(18)</sup>  $T_3$  has also been associated with protecting LDL from oxidation. <sup>(19)</sup>

Thyroid hormones can influence HDL metabolism by increasing cholesteryl ester transfer protein (CETP) activity, which exchanges cholesteryl esters from HDL<sub>2</sub> to the very low density lipoproteins (VLDL) and TGs to the opposite direction. <sup>(20)</sup> In addition, thyroid hormones stimulate the lipoprotein lipase (LPL), which catabolizes the TG-rich lipoproteins, and the hepatic lipase (HL), which hydrolyzes HDL<sub>2</sub> to HDL<sub>3</sub> and contributes to the conversion of intermediate-density lipoproteins (IDL) to LDL and in turn LDL to small dense LDL (sdLDL). <sup>(21,22)</sup> Another effect of  $T_3$  is the up-regulation of apolipoprotein AV (ApoAV), which plays a major role in TG regulation. <sup>(23)</sup> Indeed, increased levels of ApoAV have been associated with decreased levels of TGs. Proposed mechanisms for this effect include the decrease of hepatic VLDL-TG production and the increase of plasma LPL levels and activity, resulting in increase of lipoprotein remnant generation due to enhanced LPL-mediated lipolysis of VLDL-TG. Moreover, a greater clearance of lipoprotein core remnants, caused by increased hepatic uptake due to an enhanced affinity for the LDL receptor, has also been ascribed to ApoAV. <sup>(24)</sup>

Kung WC et al found thyroid hormones modulate the lipoprotein status. <sup>(25)</sup>

Following the above considerations, we have estimated lipid profile, SOD and ceruloplasmin in hyperthyroid patients, and tried to find any correlations exist between them.

## MATERIALS AND METHODS

**Study design:** Cross sectional, observational study without any type of intervention.

**Duration of study:** The duration of study was 6 months (1.7.2013 to 31.12.2013).

**Selection of cases and controls:** A total of 41 hyperthyroid (16 males and 25 females, aged 30 to 60 years) patients were selected for the study. Written informed consent was taken from them. 32 age and sex matched controls were also selected, with consent, from apparently healthy persons who were not suffering from any diseases.

**Inclusion criteria:** Selection was done according to method of convenience. All patients, for estimation of thyroid status (T4 and TSH), are according to the advice of physicians and Surgeons of different departments of the institution.

**Exclusion criteria:**

- Patients suffering from any other endocrine disorders like diabetes mellitus.
- Any other disease which may cause abnormal lipid profile, ceruloplasmin or SOD levels.
- Antenatal mothers and psychiatry patients.
- Smokers and tobacco chewers.
- Patients taking antithyroid drugs and normal thyroid status.

**Ethical Clearance:** Before commencement of the work, Ethical Clearance was obtained from the Institutional Ethics Committee, according to the Helsinki Declaration. Written informed consent was taken from cases and control subjects.

**Methods for analysis of test parameters:**

The assessment of cases and controls was done under 3 headings, history, clinical examination, and biochemical assay. For biochemical assay, 5 ml of blood from the subjects was collected aseptically using standard protocols. The serum was separated by centrifugation (3000 rpm for 5 min) immediately and analysis was done. Estimation of T4 was done by Competitive ELISA. <sup>(26)</sup> (Aspen Laboratories Pvt Ltd). Estimation of TSH was done by Sandwich Elisa. <sup>(27)</sup> (Aspen Laboratories Pvt Ltd) Serum ceruloplasmin is measured by Ravin's method. <sup>(28)</sup>

Serum SOD is measured by Kakkars method <sup>(29)</sup> Serum total cholesterol (TC) by CHOD/ PAP method <sup>(30)</sup> (Crest Biosystems), triglyceride (TG) by GPO/PAP method <sup>(31)</sup> (Crest Biosystems) (S) LDL by Direct method <sup>(32)</sup> (Erba Lachema, diagnostics). (S) HDL by PEG/CHOD-PAP method <sup>(33)</sup> (Crest Biosystems).


**Statistical Analysis:** The values of all measured parameters were grouped and tabulated. The data were expressed as mean  $\pm$  standard deviation. The Student t test was used for evaluation of the significance of difference in means of different groups. Pearson correlation was applied to test for association between the parameters where p value is significant between the control and case groups, p value less  $< 0.05$  was considered as statistically significant.

## RESULTS

**Table 1:** showing mean, standard deviation, significance and standard error of mean(case group) of the selected parameters of control and case groups.

| Parameters        | Controls(n=32)<br>(mean $\pm$ SD) | Cases(n=41)<br>(mean $\pm$ SD) | SEM    | P value    |
|-------------------|-----------------------------------|--------------------------------|--------|------------|
| T4                | 5.9 $\pm$ 1.10                    | 21.12 $\pm$ 6.8                | 1.06   | P<0.0001*  |
| TSH               | 2.9 $\pm$ 0.37                    | 0.2 $\pm$ 0.02                 | 0.0031 | P<0.0001*  |
| Ceruloplasmin     | 31.9 $\pm$ 3.08                   | 50.48 $\pm$ 3.67               | 0.57   | P<0.0001*  |
| SOD               | 3.78 $\pm$ 1.37                   | 6.96 $\pm$ 1.35                | 0.21   | P<0.0001*  |
| Total Cholesterol | 166.2 $\pm$ 1.41                  | 169.3 $\pm$ 1.44               | 0.22   | p>0.05(NS) |
| Triglyceride      | 142.4 $\pm$ 1.35                  | 139.3 $\pm$ 1.78               | 0.27   | p>0.05(NS) |
| HDL               | 47.9 $\pm$ 1.40                   | 35.5 $\pm$ 2.39                | 0.37   | P<0.05*    |
| LDL               | 76.3 $\pm$ 1.67                   | 78.4 $\pm$ 1.78                | 0.27   | p>0.05(NS) |

P value \*Indicates significance. NS means not significant.



Graph 1 showing the correlation between serum TSH and serum HDL.

Results of our study have clearly shown that (Table 1) the serum T4, ceruloplasmin and SOD are significantly high(  $p < 0.0001$  ), whereas serum TSH and HDL cholesterol are significantly low(  $p < 0.0001$  ) in hyperthyroid patients in comparison to controls. No significant alteration was observed in serum cholesterol, triglyceride and LDL levels among disease group and controls. Graph 1 has shown the positive correlation between serum TSH and serum HDL ( $r = 0.9642$ ,  $p < 0.05$ ).

## DISCUSSION

Present study has shown that, the antioxidants namely ceruloplasmin and SOD are significantly increased in hyperthyroid patients. Our study is in agreement with some previous studies. (16,34,35) Konstantions G (35) showed that hyperthyroidism increases lipid peroxidation. This finding is in agreement with previous reports indicating that the hypermetabolic state in hyperthyroidism is associated with increases in free radical production and lipid peroxide levels (36,37) Their study provides evidence that hyperthyroidism is associated with oxidative stress on DNA.

Serum ceruloplasmin levels were significantly higher in the hyperthyroid animals reflecting a greater oxidant stress.

Ceruloplasmin is a copper-binding protein with well-documented antioxidant properties. Recent report revealed its capacity to promote vasculopathic effects that include lipid oxidation, negation of nitric oxide bioactivity and endothelial cell apoptosis. (38) Through these effects, elevated circulating ceruloplasmin levels have been associated with an increased risk for cardiovascular disease. (39)

We found significant increase of SOD in hyperthyroid patients. Our study corroborates with the study of Dave BN et al. (12) Experimental investigations of ROS-scavenging enzymes in erythrocytes of several species showed SOD may be constitutively present only at low levels but highly inducible under oxidative stress while GPx is normally abundant and less inducible. (39)

Similar observations were made for erythrocyte enzymes in Graves' disease patients (40) revealing significant induction of SOD activity. We didn't observe any correlation of ceruloplasmin and sod with TSH. In our study we also analyses lipid profile. We didn't observe any significant alteration of (S) total cholesterol, triglyceride, and LDLc, but observed decreased HDLc concentration in hyperthyroid patients. Our study is in agreement with the findings of Rizos CV et al, (17) they explained despite the increased activity of the HMG-CoA reductase, levels of TC, LDL-C, ApoB and Lp(a) tend to decrease in patients with clinical or subclinical hyperthyroidism. This is due to increased LDL receptor gene expression resulting in enhanced LDL receptor-mediated catabolism of LDL particles. (41,42) Triglyceride levels also remain unchanged observed by them. We found a positive correlation between (S) HDL and TSH in hyperthyroidism. ( $r = 0.9642$ ,  $p < 0.05$ )

A decrease in HDL-C levels is also observed in hyperthyroidism, due to increased CETP-mediated transfer of cholesteryl esters from HDL to VLDL and

increased HL-mediated catabolism of HDL2. (41,42) According to the statement of Kung WC et al, (25) since hyperthyroidism is associated with decreased HDLc but increased Apo A1 concentration, which needs verification of determination of HDL2 and HDL3 concentrations in these patients. Altered lipoprotein composition together with decreased cholesterol ester transfer activity has been observed in hypothyroidism. Change in cholesterol/cholesteryl ester molar ratio in HDL was inversely related to that of cholesterol ester transfer activity during treatment of hypothyroidism which accounts for higher HDL and free cholesterol/cholesteryl ester ratio in hypothyroid state. This finding supports their observation of decreased HDLc in hyperthyroid patients.

In agreement with the following observations, we found a positive correlation between serum TSH and serum HDL. Now we can hypothesize that with decrease of TSH in hyperthyroidism, serum HDL also decreases. Excess thyroid hormone modulates lipid profile particularly HDLc.

From the results of our study, we can predict that due to increased circulating ceruloplasmin and decreased HDL levels, there is more chance of cardiovascular disease (CVD) in hyperthyroidism.

## CONCLUSION

Hyperthyroidism increases oxidative stress. Thyroid hormone also influences lipid profile. We measured serum ceruloplasmin and SOD as antioxidants in hyperthyroid patients as well as lipid profile. Our results have shown that the antioxidants are significantly increased in them reflecting oxidative stress. Serum HDLc is significantly decreased reflecting the influence of excess thyroid hormone over lipoprotein metabolism. The only positive

correlation found between(S) TSH and (HDL).

## REFERENCES

1. Kochupillai N. Clinical endocrinology in India. *Current Science* 2000; 79(8):1061-1066.
2. Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. *N Engl J Med* 1994; 331: 1072-78.
3. Ludgate M, Crips M, Lance C, Costagliola S, Vassart G, Weetman A et al. The thyrotropin receptor in thyroid eye disease. *Thyroid* 1998; 8: 411-23.
4. Kung AW. Life events, daily stresses and coping in patients with Graves' disease. *Clin Endocrinol.- Oxf.* 1995; 42: 303-8.
5. Usha Menon V, Sundaram KR, Unnikrishnan AG, Jayakumar RV, Nair V, Kumar H. High prevalence of undetected thyroid disorders in an iodine sufficient adult south Indian population. *J Indian Med Assoc* 2009; 107:72-7.
6. Abraham R, Murugan VS, Pukazhvanthen P, Sen SK. Thyroid Disorders In Women of Puducherry. *Indian J Clin Biochem* 2009;24:52-9.
7. Ozdem S, Aliciquzel Y, Ozdem SS, Karayalcin U. Effects of propylthiouracil treatment on antioxidant activities in blood of toxic multinodular goiter. *Int jour of experimental and clinical pharmacol* 2000;61(1):31-6.
8. Venditti P, Balestrieri M, Meo S, Leo T. Effect of thyroid state on lipid peroxidation, antioxidant defenses and susceptibility to oxidative stress in rat tissues. *J Endocrinol* 1997;155:151-57.
9. Munevver A, Mine I, Aysen A, Belgin E. Effects of Propylthiouracil, Propanolol and Vitamin E on lipid peroxidation and antioxidant status in hyperthyroid patients. *Clin Biochem* 1999; 32: 363-67
10. McCord JM, Fridovich I. Superoxide dismutase an enzymic function for erythrocyte. *J Biol Chem* 1969; 244: 6049-55.

11. Weisiger RA, Fridovich I. Mitochondrial superoxide dismutase. Site of synthesis and intramitochondrial localization. *J Biol Chem* 1973; 248: 4793-96.
12. Dave BM, Paradkar NM. Total superoxide dismutase, cu/zn superoxide dismutase, and glutathione peroxidase in untreated hyperthyroidism and hypothyroidism. *JK Science* 2009;11(1):6-10.
13. Katarzyna K, Kryatyna O, Eugene K, Czeslaw M, Katarzyna W, Anna K. Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease during therapy. *Clin Chim Acta* 2000 300: 107-17.
14. Kehrer JP. Free radicals as mediators of tissue injury and disease. *Crit Rev Toxicol* 1993; 23: 21-48.
15. Harman D. Aging and oxidative stress. *JIFCC* 1998; 10: 24-27.
16. Dumitriu L, Bartok R, Ursu H, Purice M, Lonescu V. Significance of high levels of serum malondialdehyde (MDA) and ceruloplasmin (CP) in hyper and hypothyroidism. *Endocrinologie* 1988;26(1):35-8.
17. Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. *Cardiovasc Med* J2011;5: 76-84.
18. Shin DJ, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2) *J Biol Chem*. 2003;278:34114
19. Faure P, Oziol L, Artur Y, Chomard P. Thyroid hormone (T3) and its acetic derivative (TA3) protect low-density lipoproteins from oxidation by different mechanisms. *Biochimie*. 2004;86:411-8.
20. Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. *Biochim Biophys Acta*. 1994;1215: 209-36
21. Kuusi T, Saarinen P, Nikkila EA. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in man. *Atherosclerosis*. 1980;36:589-93
22. Santamarina-Fojo S, Gonzalez-Navarro H, Freeman L, Wagner E, Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. *Arterioscler Thromb Vasc Biol*. 2004;24:1750-4.
23. Prieur X, Huby T, Coste H, Schaap FG, Chapman MJ, Rodriguez JC. Thyroid hormone regulates the hypotriglyceridemic gene APOA5. *J Biol Chem*. 2005;280:27533-43.
24. Rensen PC, van Dijk KW, Havekes LM. Apolipoprotein AV: low concentration, high impact. *Arterioscler Thromb Vasc Biol*. 2005; 25:2445-7.
25. Kung WC, Pang WC, Lauder I, Lam SL, Janus ED. Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism. *Clin chem* 1995; 41(2):226-31.
26. Surks MI, Chopra IJ, Mariash CN, Nicoloff JT, Solomon DH. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. *JAMA*. 1990;263(11):1529-1533.
27. Walker WH. An approach to immunoassay. *Clin. Chem*. 1977;23: 384-402.
28. Ravin HA. An improved colorimetric enzymatic assay of ceruloplasmin. *J Lab Clin Med* 1961;58:161-8.
29. Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. *Ind J Biochem Biophys*. 1984;21:130-2.
30. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. *Clin Chem* 1978;20:470-5.
31. Ziegenhorn J. Improved method for enzymatic determination of serum triglyceride. *Clin Chem* 1975;21(11): 1627-9.
32. Pisani T, Gebiski CP, Leary ET et al. Accurate direct determination of low density lipoprotein cholesterol assay. *Arch Pathol Lab Med* 1995; 119: 1127.
33. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, et al. Direct measurement of high density

- lipoprotein cholesterol in serum with polyethylene Glycol-Modified enzymes and Sulfated alpha-cyclodextrin. *Clin Chem* 1995;41:717-23.
34. Erkilic AR, Aliciguzel Y, Erkilic M, Aksu A. Ceruloplasmin and vitamin E levels in toxic multinodular goitre. *Nutrition Research* 1996; 16(2): 185-89.
  35. Moulakakis KG, Poulakou MV, Paraskevas KI, Doutas I, Vlachos IS, Perrea D et al. Hyperthyroidism is associated with increased aortic oxidative DNA damage in a rat model. *In vivo* 2007;21: 1021-1026.
  36. Fernandez V, Barrientos X, Kipreos K, Valenzuela A and Videla LA: Superoxide radical generation, NADPH oxidase activity, and cytochrome P-450 content of rat liver microsomal fractions in an experimental hyperthyroid state: relation to lipid peroxidation. *Endocrinology* 117: 496-501, 1985.
  37. Asayama K, Dobashi K, Hayashibe H and Kato K: Vitamin E protects against thyroxine-induced acceleration of lipid peroxidation in cardiac and skeletal muscles in rats. *J Nutr Sci Vitaminol (Tokyo)* 35: 407-418, 1989.
  38. Shukla N, Maher J, Masters J, Angelini GD and Jeremy JY: Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? *Atherosclerosis* 187: 238-250, 2006.
  39. Maral J, Puget K, Michelson AM. Comparative study of superoxide dismutase activity, catalase and glutathione peroxidase levels in erythrocytes of different animals. *Biochem Biophys Res Commun* 1977; 77: 1525-535.
  40. Seven R, Gelisgen R, Seven A, Erbil Y, Bozbora A, Burcak G. Influence of propylthiouracil treatment on oxidative stress and nitric oxide in Basedow disease patients. *J Toxicol Environ Health Part A* 2001; 62: 495-503.
  41. Kung AW, Pang RW, Lauder I, Lam KS, Janus ED. Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism. *Clin Chem.* 1995;41:226-31.
  42. Aviram M, Luboshitzky R, Brook JG. Lipid and lipoprotein pattern in thyroid dysfunction and the effect of therapy. *Clin Biochem.* 1982;15:62-6.

How to cite this article: Kar K, Sinha S. Positive correlation found between HDL and TSH in hyperthyroidism. *Int J Health Sci Res.* 2015; 5(11):173-179.

\*\*\*\*\*